RU2013144571A - Алинзамещенные хиназолины и способы их применения - Google Patents
Алинзамещенные хиназолины и способы их применения Download PDFInfo
- Publication number
- RU2013144571A RU2013144571A RU2013144571/04A RU2013144571A RU2013144571A RU 2013144571 A RU2013144571 A RU 2013144571A RU 2013144571/04 A RU2013144571/04 A RU 2013144571/04A RU 2013144571 A RU2013144571 A RU 2013144571A RU 2013144571 A RU2013144571 A RU 2013144571A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- cancer
- cycloalkyl
- compound according
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449088P | 2011-03-04 | 2011-03-04 | |
| US61/449,088 | 2011-03-04 | ||
| PCT/US2012/027614 WO2012122058A2 (en) | 2011-03-04 | 2012-03-02 | Alkyne substituted quinazoline compound and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013144571A true RU2013144571A (ru) | 2015-04-10 |
Family
ID=46798728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013144571/04A RU2013144571A (ru) | 2011-03-04 | 2012-03-02 | Алинзамещенные хиназолины и способы их применения |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9090588B2 (enExample) |
| EP (1) | EP2680850B1 (enExample) |
| JP (1) | JP6006242B2 (enExample) |
| KR (4) | KR20210043016A (enExample) |
| CN (1) | CN103998040B (enExample) |
| AU (3) | AU2012225693A1 (enExample) |
| BR (1) | BR112013022552B1 (enExample) |
| CA (1) | CA2828713C (enExample) |
| IL (1) | IL228072A (enExample) |
| MX (1) | MX344302B (enExample) |
| RU (1) | RU2013144571A (enExample) |
| SG (3) | SG193291A1 (enExample) |
| TW (1) | TWI617556B (enExample) |
| WO (1) | WO2012122058A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG193291A1 (en) | 2011-03-04 | 2013-10-30 | Newgen Therapeutics Inc | Alkyne substituted quinazoline compound and methods of use |
| CN102918029B (zh) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
| JP6437820B2 (ja) * | 2011-07-27 | 2018-12-12 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | キナゾリン誘導体、その製造方法、中間体、組成物及びその適用 |
| CN104119350B (zh) | 2013-04-28 | 2017-04-12 | 广东东阳光药业有限公司 | 氨基喹唑啉类衍生物及其盐和使用方法 |
| CN103254156B (zh) * | 2013-05-10 | 2015-08-26 | 苏州明锐医药科技有限公司 | 阿法替尼中间体的制备方法 |
| CN103254183B (zh) * | 2013-05-10 | 2015-11-11 | 苏州明锐医药科技有限公司 | 阿法替尼的制备方法 |
| CA3228632A1 (en) * | 2015-12-24 | 2017-06-29 | Kyowa Kirin Co., Ltd. | .alpha.,.beta.-unsaturated amide compound |
| DE102016224889B4 (de) * | 2016-12-14 | 2019-11-07 | Airbus Defence and Space GmbH | Verfahren zur Vorbeugung einer Ablösung einer Fluidströmung, Strömungskörpersystem und Luftfahrzeug |
| US11083492B2 (en) * | 2018-06-06 | 2021-08-10 | Lifetech Scientific (Shenzhen) Co., Ltd | Method for implanting an interventional medical device |
| US10973321B2 (en) | 2018-09-04 | 2021-04-13 | Steelcase Inc. | Workspace system and components and method for the use thereof |
| EP3856726A1 (en) | 2018-09-25 | 2021-08-04 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use |
| US12435046B2 (en) * | 2019-08-15 | 2025-10-07 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CN113527215B (zh) * | 2020-04-17 | 2023-12-05 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| WO2021209039A1 (zh) * | 2020-04-17 | 2021-10-21 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、制备方法及其应用 |
| WO2022094464A1 (en) * | 2020-11-02 | 2022-05-05 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2024179451A1 (zh) * | 2023-03-02 | 2024-09-06 | 江苏康缘药业股份有限公司 | 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4062881A (en) | 1974-07-26 | 1977-12-13 | Cincinnati Milacron Chemicals, Inc. | Sulfide containing tin stabilizers |
| US4343940A (en) | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| GB2160201B (en) | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| EP0326307B1 (en) | 1988-01-23 | 1994-08-17 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
| US5053227A (en) | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| JP3089901B2 (ja) | 1993-07-20 | 2000-09-18 | 株式会社豊田自動織機製作所 | クラッチレス圧縮機における動力伝達構造 |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| GB9405355D0 (en) | 1994-03-18 | 1994-05-04 | Lucas Ind Plc | Vibrating element transducer |
| WO1996029331A1 (de) | 1995-03-20 | 1996-09-26 | Dr. Karl Thomae Gmbh | Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| EP0817775B1 (en) | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| WO1996035689A1 (en) | 1995-05-12 | 1996-11-14 | Neurogen Corporation | Novel deazapurine derivatives; a new class of crf1 specific ligands |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507052A (ja) | 1995-06-07 | 1999-06-22 | スージェン・インコーポレーテッド | キナゾリンおよび医薬組成物 |
| SK72996A3 (en) | 1995-06-07 | 1997-04-09 | Pfizer | Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| AU2522197A (en) | 1996-04-16 | 1997-11-07 | Ube Industries, Ltd. | Hydrazine compounds, process for the preparation thereof, and insecticides for agricultural and horticultural use |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| AU5391099A (en) | 1998-07-30 | 2000-02-21 | American Home Products Corporation | Substituted quinazoline derivatives |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US6627634B2 (en) | 2000-04-08 | 2003-09-30 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
| KR100815681B1 (ko) | 2000-06-30 | 2008-03-20 | 글락소 그룹 리미티드 | 퀴나졸린 디토실레이트 염 화합물 |
| DK1332137T3 (da) | 2000-10-27 | 2006-07-17 | Novartis Ag | Behandling af gastrointestinale stromale tumorer |
| DE10063435A1 (de) | 2000-12-20 | 2002-07-04 | Boehringer Ingelheim Pharma | Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US7294629B2 (en) * | 2001-02-21 | 2007-11-13 | Mitsubishi Pharma Corporation | Quinazoline derivatives |
| TW200813014A (en) | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| GB0215823D0 (en) * | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| DE10349113A1 (de) | 2003-10-17 | 2005-05-12 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Aminocrotonylverbindungen |
| JP4353903B2 (ja) | 2005-01-07 | 2009-10-28 | 東京エレクトロン株式会社 | クラスタツールの処理システム |
| KR20080016671A (ko) * | 2005-05-25 | 2008-02-21 | 와이어쓰 | 치환된 3-시아노퀴놀린 및 그것의 중간체를 합성하는 방법 |
| CA2629244C (en) | 2005-11-11 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
| CA2639936C (en) | 2006-01-26 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Process for preparing aminocrotonylamino-substituted quinazoline derivatives |
| CN100345856C (zh) | 2006-03-10 | 2007-10-31 | 武汉化工学院 | 一种制备葡萄糖醛酸内酯的酯化及结晶工艺方法 |
| JP5580592B2 (ja) | 2006-09-11 | 2014-08-27 | キュリス，インコーポレイテッド | 亜鉛結合部分を含むキナゾリン系ｅｇｆｒインヒビター |
| WO2008119663A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CN101584696A (zh) | 2008-05-21 | 2009-11-25 | 上海艾力斯医药科技有限公司 | 包含喹唑啉衍生物的组合物及制备方法、用途 |
| CN102686581B (zh) | 2009-12-21 | 2015-08-26 | 张强 | 喹唑啉衍生物 |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CN102382106A (zh) | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| SG193291A1 (en) | 2011-03-04 | 2013-10-30 | Newgen Therapeutics Inc | Alkyne substituted quinazoline compound and methods of use |
| CN102918029B (zh) | 2011-05-17 | 2015-06-17 | 江苏康缘药业股份有限公司 | 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途 |
-
2012
- 2012-03-02 SG SG2013066352A patent/SG193291A1/en unknown
- 2012-03-02 EP EP12754325.4A patent/EP2680850B1/en active Active
- 2012-03-02 JP JP2013556664A patent/JP6006242B2/ja active Active
- 2012-03-02 RU RU2013144571/04A patent/RU2013144571A/ru not_active Application Discontinuation
- 2012-03-02 CN CN201280011384.6A patent/CN103998040B/zh active Active
- 2012-03-02 AU AU2012225693A patent/AU2012225693A1/en not_active Abandoned
- 2012-03-02 KR KR1020217010767A patent/KR20210043016A/ko not_active Ceased
- 2012-03-02 BR BR112013022552-1A patent/BR112013022552B1/pt active IP Right Grant
- 2012-03-02 SG SG10201913982WA patent/SG10201913982WA/en unknown
- 2012-03-02 SG SG10201601711SA patent/SG10201601711SA/en unknown
- 2012-03-02 KR KR1020197038395A patent/KR20200003933A/ko not_active Ceased
- 2012-03-02 US US14/002,983 patent/US9090588B2/en active Active
- 2012-03-02 MX MX2013010016A patent/MX344302B/es active IP Right Grant
- 2012-03-02 KR KR1020227006071A patent/KR20220031732A/ko not_active Ceased
- 2012-03-02 WO PCT/US2012/027614 patent/WO2012122058A2/en not_active Ceased
- 2012-03-02 KR KR1020137026199A patent/KR102061743B1/ko active Active
- 2012-03-02 CA CA2828713A patent/CA2828713C/en active Active
- 2012-03-03 TW TW101107247A patent/TWI617556B/zh active
-
2013
- 2013-08-22 IL IL228072A patent/IL228072A/en active IP Right Grant
-
2015
- 2015-06-19 US US14/745,308 patent/US20160031860A1/en not_active Abandoned
-
2017
- 2017-02-14 AU AU2017200984A patent/AU2017200984A1/en not_active Abandoned
- 2017-08-11 US US15/675,438 patent/US20180093975A1/en not_active Abandoned
-
2018
- 2018-11-22 AU AU2018267622A patent/AU2018267622B2/en active Active
-
2019
- 2019-01-18 US US16/252,458 patent/US20190382382A1/en not_active Abandoned
-
2020
- 2020-03-27 US US16/833,020 patent/US11524956B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2014518544A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2013131004A (ru) | Комбинация (а) ингибитора фосфоинозит-3-киназы и (б) модулятора пути ras/raf/mek | |
| JP2016530283A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| RU2018119173A (ru) | Производное бензофурана, способ его получения и его применение в медицине | |
| RU2013148732A (ru) | Комбинации соединений, ингибирующих акт, и химиотерапевтических агентов и способы их применения | |
| HRP20141094T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| JP2014512356A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| RU2018106453A (ru) | Соединения | |
| RU2016140420A (ru) | Производное 1,3-бензодиоксола | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| JP2009513703A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| RU2016134751A (ru) | Соединения | |
| WO2018152548A4 (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| RU2016122731A (ru) | Функционализированные и замещенные индолы в качестве противораковых агентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170410 |